Genmab A/ S stock (DK0010272202): shares under pressure on Nasdaq Copenhagen amid oncology competition focus

Genmab A/S shares slipped on Nasdaq Copenhagen as investors digested fresh competitor data from Johnson & Johnson, sharpening attention on the Danish biotech’s positioning in the oncology antibody market.

Genmab A/S shares traded lower on Nasdaq Copenhagen on 06/03/2026 as investors reassessed the Danish biotech’s prospects in oncology antibodies following new clinical trial data from competitor Johnson & Johnson that weighed on sentiment in the sector, according to Reuters as of 06/03/2026.

The stock, listed on Nasdaq Copenhagen under the ticker GMAB, changed hands at around DKK 1,980 in Wednesday trading, down roughly 1.6% on the day with volumes modestly above the 20-day average, according to Nasdaq Nordic price data as of 06/03/2026.

For investors in Denmark, the move keeps Genmab’s market capitalization near DKK 130 billion and places renewed emphasis on how its antibody pipeline stacks up against global pharmaceutical peers in key oncology indications, based on Nasdaq Copenhagen data as of 06/03/2026.

In Germany, Genmab shares were also quoted on Tradegate in euro, with the stock around EUR 265 on 06/03/2026 in relatively light afternoon trading, according to Tradegate price information as of 06/03/2026.

Beyond the immediate price reaction, the latest competitor readout has turned attention back to how Genmab balances partnered programs with its own proprietary assets in a competitive market for novel antibody-based cancer therapies, as reflected in coverage from financial media on 06/03/2026.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Genmab
• Sector/industry: Biotechnology - antibody-based therapeutics
• Headquarters/country: Copenhagen, Denmark
• Core markets: Europe, United States, Japan
• Key revenue drivers: Oncology antibody therapies and royalty streams from partnered products
• Home exchange/listing venue: Nasdaq Copenhagen (GMAB)
• Trading currency: DKK

Genmab A/S: core business model

Genmab focuses on discovering and developing antibody-based medicines, with revenue primarily generated through a mix of product sales, collaboration milestones, and royalties from cancer therapies marketed with global pharmaceutical partners.

Genmab A/S in peer comparison

On the mid-week session of 06/03/2026, Genmab traded on Nasdaq Copenhagen at a level that implied a market capitalization close to DKK 130 billion, placing it among the larger pure-play biotech names in the Nordic region when compared with peers focused on innovative therapies.

Against international competitors in oncology antibodies, such as Danish neighbor Novo Nordisk in metabolic disease and larger US-focused biotech platforms listed on Nasdaq, Genmab’s size and focus differentiate it as a specialist in antibody technology rather than a diversified pharmaceutical group, according to sector comparisons from MarketScreener as of 06/03/2026.

Conclusion

The latest decline in Genmab’s share price on Nasdaq Copenhagen highlights how quickly sentiment in Denmark’s biotech segment can react to competitor oncology data and broader sector news flow.

In a peer context, the company remains one of the more sizeable antibody-focused players in the Nordic market, with a specialist profile that continues to be judged against both regional innovators and larger global pharmaceutical groups.

Investors will watch upcoming clinical and regulatory milestones, as well as any further competitive updates, to gauge how Genmab’s positioning in oncology antibodies evolves relative to its peers.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.